Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

• Main Authors: Yuan-Pin Hung (Author), Jen-Chieh Lee (Author), Chun-Wei Chiu (Author), Ching-Chi Lee (Author), Pei-Jane Tsai (Author), I-Lin Hsu (Author), Wen-Chien Ko (Author)
• Format: Book
• Published: MDPI AG, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (M^pro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir/ritonavir within five day...